ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.
Alicia Morgans, MD, MPH
Advertisement
Articles by Alicia Morgans, MD, MPH
ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL
3
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
4
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
5